内皮功能障碍和心力衰竭与保存的喷射分数 - - 一个最新的文献评论
Mariarosaria De Luca1,2, Giulia Crisci1,2, Giuseppe Armentaro3
1Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy.
Life (Basel, Switzerland)
|January 23, 2024
概括
内皮功能障碍 (ED) 是心力衰竭 (HF) 进展的关键因素,影响患者的结果. 通过各种疗法准ED显示出改善心力衰竭管理的希望.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 病理生理学 病理生理学
背景情况:
- 心力衰竭 (HF) 涉及到导致压力/输出问题的心脏异常.
- 内皮功能障碍 (ED) 是高血压的主要特征,影响血管健康.
- 勃起障碍的表现会影响全身,肺,和冠状动脉循环.
研究的目的:
- 审查ED在HF病理生理学中的作用,特别是具有保留射出分数的HF.
- 为了检查ED对HF患者的影响.
- 讨论在HF中治疗ED的潜在治疗策略.
主要方法:
- 在PubMed,Scopus,EMBASE和Medline的文献搜索.
- 评估ED通过静脉封闭囊学或流量介导扩张的研究的审查.
- 对药理和非药理干预措施的分析.
主要成果:
- 勃起障碍与HF患者的不良结果独立相关,包括死亡率和住院治疗.
- 一些干预措施,包括SGLT2抑制剂和运动训练,可以积极调节高频率患者的ED.
- 像流介扩张这样的ED评估方法与HF预后相关.
结论:
- 内皮功能障碍是导致心力衰竭的重要因素.
- 针对ED提供了一个有希望的治疗途径,用于管理心力衰竭.
- 需要进一步的研究,以充分阐明血管内皮在HF中的作用.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341


